Breakthrough status for Tardive Dyskinesia treatment

The US FDA has granted Breakthrough Therapy Designation status to Israel’s Teva for its SD-809 (deutetrabenazine) treatment of patients with tardive dyskinesia, a hyperkinetic movement disorder affecting about 500,000 people in the USA.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *